
### [MONDO:0015901](http://purl.obolibrary.org/obo/MONDO_0015901)
**Label:** rare hyperlipidemia

**Subclasses:** [MONDO:0016203](http://purl.obolibrary.org/obo/MONDO_0016203) (hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency), [MONDO:0018328](http://purl.obolibrary.org/obo/MONDO_0018328) (homozygous familial hypercholesterolemia), [MONDO:0011470](http://purl.obolibrary.org/obo/MONDO_0011470) (hyperlipidemia, combined, 2), [MONDO:0011374](http://purl.obolibrary.org/obo/MONDO_0011374) (autosomal recessive hypercholesterolemia), [MONDO:0001807](http://purl.obolibrary.org/obo/MONDO_0001807) (familial combined hyperlipidemia), [MONDO:0007327](http://purl.obolibrary.org/obo/MONDO_0007327) (chylomicronemia, familial, due to circulating inhibitor of lipoprotein lipase), [MONDO:0007788](http://purl.obolibrary.org/obo/MONDO_0007788) (hypertriglyceridemia, familial), [MONDO:0007744](http://purl.obolibrary.org/obo/MONDO_0007744) (cholesterol-ester transfer protein deficiency), [MONDO:0007762](http://purl.obolibrary.org/obo/MONDO_0007762) (hyperlipoproteinemia type V), [MONDO:0011237](http://purl.obolibrary.org/obo/MONDO_0011237) (hyperlipidemia, combined, 1), [MONDO:0013533](http://purl.obolibrary.org/obo/MONDO_0013533) (hyperlipidemia due to hepatic triglyceride lipase deficiency), [MONDO:0013534](http://purl.obolibrary.org/obo/MONDO_0013534) (apolipoprotein c-Iii deficiency), [MONDO:0014789](http://purl.obolibrary.org/obo/MONDO_0014789) (CCDC115-CDG), [MONDO:0018799](http://purl.obolibrary.org/obo/MONDO_0018799) (rare hypercholesterolemia), [MONDO:0014412](http://purl.obolibrary.org/obo/MONDO_0014412) (hyperlipoproteinemia, type 1D), [MONDO:0014790](http://purl.obolibrary.org/obo/MONDO_0014790) (TMEM199-CDG), [MONDO:0009387](http://purl.obolibrary.org/obo/MONDO_0009387) (familial lipoprotein lipase deficiency), [MONDO:0018473](http://purl.obolibrary.org/obo/MONDO_0018473) (hyperlipoproteinemia type 3), [MONDO:0008810](http://purl.obolibrary.org/obo/MONDO_0008810) (familial apolipoprotein C-II deficiency), [MONDO:0007759](http://purl.obolibrary.org/obo/MONDO_0007759) (hyperlipidemia, familial combined, LPL related), [MONDO:0015903](http://purl.obolibrary.org/obo/MONDO_0015903) (hyperalphalipoproteinemia), [MONDO:0015308](http://purl.obolibrary.org/obo/MONDO_0015308) (laminopathy type Decaudain-Vigouroux), [MONDO:0015902](http://purl.obolibrary.org/obo/MONDO_0015902) (major hypertriglyceridemia), [MONDO:0011207](http://purl.obolibrary.org/obo/MONDO_0011207) (xanthomatosis, susceptibility to), [MONDO:0018637](http://purl.obolibrary.org/obo/MONDO_0018637) (familial chylomicronemia syndrome), 

**Mapped go classes:** [GO:1905146](http://purl.obolibrary.org/obo/GO_1905146) (lysosomal protein catabolic process), [GO:0046337](http://purl.obolibrary.org/obo/GO_0046337) (phosphatidylethanolamine metabolic process), [GO:0046461](http://purl.obolibrary.org/obo/GO_0046461) (neutral lipid catabolic process), [GO:0051005](http://purl.obolibrary.org/obo/GO_0051005) (negative regulation of lipoprotein lipase activity), [GO:0005902](http://purl.obolibrary.org/obo/GO_0005902) (microvillus), [GO:0097006](http://purl.obolibrary.org/obo/GO_0097006) (regulation of plasma lipoprotein particle levels), [GO:0010897](http://purl.obolibrary.org/obo/GO_0010897) (negative regulation of triglyceride catabolic process), [GO:0070325](http://purl.obolibrary.org/obo/GO_0070325) (lipoprotein particle receptor binding), [GO:0010898](http://purl.obolibrary.org/obo/GO_0010898) (positive regulation of triglyceride catabolic process), [GO:0070328](http://purl.obolibrary.org/obo/GO_0070328) (triglyceride homeostasis), [GO:0030301](http://purl.obolibrary.org/obo/GO_0030301) (cholesterol transport), [GO:0071813](http://purl.obolibrary.org/obo/GO_0071813) (lipoprotein particle binding), [GO:0030300](http://purl.obolibrary.org/obo/GO_0030300) (regulation of intestinal cholesterol absorption), [GO:0030663](http://purl.obolibrary.org/obo/GO_0030663) (COPI-coated vesicle membrane), [GO:0051006](http://purl.obolibrary.org/obo/GO_0051006) (positive regulation of lipoprotein lipase activity), [GO:0034185](http://purl.obolibrary.org/obo/GO_0034185) (apolipoprotein binding), [GO:0060230](http://purl.obolibrary.org/obo/GO_0060230) (lipoprotein lipase activator activity), [GO:0006695](http://purl.obolibrary.org/obo/GO_0006695) (cholesterol biosynthetic process), [GO:0046983](http://purl.obolibrary.org/obo/GO_0046983) (protein dimerization activity), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0005764](http://purl.obolibrary.org/obo/GO_0005764) (lysosome), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0046470](http://purl.obolibrary.org/obo/GO_0046470) (phosphatidylcholine metabolic process), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:0046475](http://purl.obolibrary.org/obo/GO_0046475) (glycerophospholipid catabolic process), [GO:0046473](http://purl.obolibrary.org/obo/GO_0046473) (phosphatidic acid metabolic process), [GO:0031102](http://purl.obolibrary.org/obo/GO_0031102) (neuron projection regeneration), [GO:0016004](http://purl.obolibrary.org/obo/GO_0016004) (phospholipase activator activity), [GO:0051259](http://purl.obolibrary.org/obo/GO_0051259) (protein oligomerization), [GO:0030137](http://purl.obolibrary.org/obo/GO_0030137) (COPI-coated vesicle), [GO:0031225](http://purl.obolibrary.org/obo/GO_0031225) (anchored component of membrane), [GO:0016746](http://purl.obolibrary.org/obo/GO_0016746) (transferase activity, transferring acyl groups), [GO:0015012](http://purl.obolibrary.org/obo/GO_0015012) (heparan sulfate proteoglycan biosynthetic process), [GO:0008320](http://purl.obolibrary.org/obo/GO_0008320) (protein transmembrane transporter activity), [GO:0008203](http://purl.obolibrary.org/obo/GO_0008203) (cholesterol metabolic process), [GO:0009897](http://purl.obolibrary.org/obo/GO_0009897) (external side of plasma membrane), [GO:0008289](http://purl.obolibrary.org/obo/GO_0008289) (lipid binding), [GO:0008047](http://purl.obolibrary.org/obo/GO_0008047) (enzyme activator activity), [GO:0008201](http://purl.obolibrary.org/obo/GO_0008201) (heparin binding), [GO:0042157](http://purl.obolibrary.org/obo/GO_0042157) (lipoprotein metabolic process), [GO:0005576](http://purl.obolibrary.org/obo/GO_0005576) (extracellular region), [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component), [GO:0042159](http://purl.obolibrary.org/obo/GO_0042159) (lipoprotein catabolic process), [GO:0003674](http://purl.obolibrary.org/obo/GO_0003674) (molecular_function), [GO:0042953](http://purl.obolibrary.org/obo/GO_0042953) (lipoprotein transport), [GO:0010916](http://purl.obolibrary.org/obo/GO_0010916) (negative regulation of very-low-density lipoprotein particle clearance), [GO:0006658](http://purl.obolibrary.org/obo/GO_0006658) (phosphatidylserine metabolic process), [GO:0070062](http://purl.obolibrary.org/obo/GO_0070062) (extracellular exosome), [GO:0010518](http://purl.obolibrary.org/obo/GO_0010518) (positive regulation of phospholipase activity), [GO:0016471](http://purl.obolibrary.org/obo/GO_0016471) (vacuolar proton-transporting V-type ATPase complex), [GO:0030121](http://purl.obolibrary.org/obo/GO_0030121) (AP-1 adaptor complex), [GO:0055102](http://purl.obolibrary.org/obo/GO_0055102) (lipase inhibitor activity), [GO:0030122](http://purl.obolibrary.org/obo/GO_0030122) (AP-2 adaptor complex), [GO:0031210](http://purl.obolibrary.org/obo/GO_0031210) (phosphatidylcholine binding), [GO:0090319](http://purl.obolibrary.org/obo/GO_0090319) (positive regulation of chylomicron remodeling), [GO:0048261](http://purl.obolibrary.org/obo/GO_0048261) (negative regulation of receptor-mediated endocytosis), [GO:0010873](http://purl.obolibrary.org/obo/GO_0010873) (positive regulation of cholesterol esterification), [GO:0033116](http://purl.obolibrary.org/obo/GO_0033116) (endoplasmic reticulum-Golgi intermediate compartment membrane), [GO:0090324](http://purl.obolibrary.org/obo/GO_0090324) (negative regulation of oxidative phosphorylation), [GO:0010890](http://purl.obolibrary.org/obo/GO_0010890) (positive regulation of sequestering of triglyceride), [GO:0090321](http://purl.obolibrary.org/obo/GO_0090321) (positive regulation of chylomicron remnant clearance), [GO:0008970](http://purl.obolibrary.org/obo/GO_0008970) (phosphatidylcholine 1-acylhydrolase activity), [GO:0005102](http://purl.obolibrary.org/obo/GO_0005102) (receptor binding), [GO:0045833](http://purl.obolibrary.org/obo/GO_0045833) (negative regulation of lipid metabolic process), [GO:0005615](http://purl.obolibrary.org/obo/GO_0005615) (extracellular space), [GO:0010886](http://purl.obolibrary.org/obo/GO_0010886) (positive regulation of cholesterol storage), [GO:0004806](http://purl.obolibrary.org/obo/GO_0004806) (triglyceride lipase activity), [GO:0033344](http://purl.obolibrary.org/obo/GO_0033344) (cholesterol efflux), [GO:0032375](http://purl.obolibrary.org/obo/GO_0032375) (negative regulation of cholesterol transport), [GO:0017038](http://purl.obolibrary.org/obo/GO_0017038) (protein import), [GO:0016589](http://purl.obolibrary.org/obo/GO_0016589) (NURF complex), [GO:0034394](http://purl.obolibrary.org/obo/GO_0034394) (protein localization to cell surface), [GO:0055096](http://purl.obolibrary.org/obo/GO_0055096) (low-density lipoprotein particle mediated signaling), [GO:0036295](http://purl.obolibrary.org/obo/GO_0036295) (cellular response to increased oxygen levels), [GO:0006641](http://purl.obolibrary.org/obo/GO_0006641) (triglyceride metabolic process), [GO:0005793](http://purl.obolibrary.org/obo/GO_0005793) (endoplasmic reticulum-Golgi intermediate compartment), [GO:0006886](http://purl.obolibrary.org/obo/GO_0006886) (intracellular protein transport), [GO:0004465](http://purl.obolibrary.org/obo/GO_0004465) (lipoprotein lipase activity), [GO:0055090](http://purl.obolibrary.org/obo/GO_0055090) (acylglycerol homeostasis), [GO:0006642](http://purl.obolibrary.org/obo/GO_0006642) (triglyceride mobilization), [GO:0004620](http://purl.obolibrary.org/obo/GO_0004620) (phospholipase activity), [GO:0045723](http://purl.obolibrary.org/obo/GO_0045723) (positive regulation of fatty acid biosynthetic process), [GO:0046658](http://purl.obolibrary.org/obo/GO_0046658) (anchored component of plasma membrane), [GO:0006879](http://purl.obolibrary.org/obo/GO_0006879) (cellular iron ion homeostasis), [GO:0005789](http://purl.obolibrary.org/obo/GO_0005789) (endoplasmic reticulum membrane), [GO:0050750](http://purl.obolibrary.org/obo/GO_0050750) (low-density lipoprotein particle receptor binding), [GO:0045056](http://purl.obolibrary.org/obo/GO_0045056) (transcytosis), [GO:0071333](http://purl.obolibrary.org/obo/GO_0071333) (cellular response to glucose stimulus), [GO:0043395](http://purl.obolibrary.org/obo/GO_0043395) (heparan sulfate proteoglycan binding), [GO:0043274](http://purl.obolibrary.org/obo/GO_0043274) (phospholipase binding), [GO:0016298](http://purl.obolibrary.org/obo/GO_0016298) (lipase activity), [GO:0035478](http://purl.obolibrary.org/obo/GO_0035478) (chylomicron binding), [GO:0050996](http://purl.obolibrary.org/obo/GO_0050996) (positive regulation of lipid catabolic process), [GO:0035473](http://purl.obolibrary.org/obo/GO_0035473) (lipase binding), [GO:0034383](http://purl.obolibrary.org/obo/GO_0034383) (low-density lipoprotein particle clearance), [GO:0017129](http://purl.obolibrary.org/obo/GO_0017129) (triglyceride binding), [GO:0034382](http://purl.obolibrary.org/obo/GO_0034382) (chylomicron remnant clearance), [GO:0008150](http://purl.obolibrary.org/obo/GO_0008150) (biological_process), [GO:0042627](http://purl.obolibrary.org/obo/GO_0042627) (chylomicron), [GO:0034380](http://purl.obolibrary.org/obo/GO_0034380) (high-density lipoprotein particle assembly), [GO:0015485](http://purl.obolibrary.org/obo/GO_0015485) (cholesterol binding), [GO:0034384](http://purl.obolibrary.org/obo/GO_0034384) (high-density lipoprotein particle clearance), [GO:0008035](http://purl.obolibrary.org/obo/GO_0008035) (high-density lipoprotein particle binding), [GO:0006810](http://purl.obolibrary.org/obo/GO_0006810) (transport), [GO:0043434](http://purl.obolibrary.org/obo/GO_0043434) (response to peptide hormone), [GO:0004622](http://purl.obolibrary.org/obo/GO_0004622) (lysophospholipase activity), [GO:0070072](http://purl.obolibrary.org/obo/GO_0070072) (vacuolar proton-transporting V-type ATPase complex assembly), [GO:0010989](http://purl.obolibrary.org/obo/GO_0010989) (negative regulation of low-density lipoprotein particle clearance), [GO:0010867](http://purl.obolibrary.org/obo/GO_0010867) (positive regulation of triglyceride biosynthetic process), [GO:0016042](http://purl.obolibrary.org/obo/GO_0016042) (lipid catabolic process), [GO:0010902](http://purl.obolibrary.org/obo/GO_0010902) (positive regulation of very-low-density lipoprotein particle remodeling), [GO:0019432](http://purl.obolibrary.org/obo/GO_0019432) (triglyceride biosynthetic process), [GO:0034379](http://purl.obolibrary.org/obo/GO_0034379) (very-low-density lipoprotein particle assembly), [GO:0010987](http://purl.obolibrary.org/obo/GO_0010987) (negative regulation of high-density lipoprotein particle clearance), [GO:0019433](http://purl.obolibrary.org/obo/GO_0019433) (triglyceride catabolic process), [GO:0010744](http://purl.obolibrary.org/obo/GO_0010744) (positive regulation of macrophage derived foam cell differentiation), [GO:0016323](http://purl.obolibrary.org/obo/GO_0016323) (basolateral plasma membrane), [GO:0016324](http://purl.obolibrary.org/obo/GO_0016324) (apical plasma membrane), [GO:0034372](http://purl.obolibrary.org/obo/GO_0034372) (very-low-density lipoprotein particle remodeling), [GO:0034371](http://purl.obolibrary.org/obo/GO_0034371) (chylomicron remodeling), [GO:0034370](http://purl.obolibrary.org/obo/GO_0034370) (triglyceride-rich lipoprotein particle remodeling), [GO:0034375](http://purl.obolibrary.org/obo/GO_0034375) (high-density lipoprotein particle remodeling), [GO:0034374](http://purl.obolibrary.org/obo/GO_0034374) (low-density lipoprotein particle remodeling), [GO:0060228](http://purl.obolibrary.org/obo/GO_0060228) (phosphatidylcholine-sterol O-acyltransferase activator activity), [GO:0005770](http://purl.obolibrary.org/obo/GO_0005770) (late endosome), [GO:0090197](http://purl.obolibrary.org/obo/GO_0090197) (positive regulation of chemokine secretion), [GO:0060229](http://purl.obolibrary.org/obo/GO_0060229) (lipase activator activity), [GO:0007035](http://purl.obolibrary.org/obo/GO_0007035) (vacuolar acidification), [GO:0042632](http://purl.obolibrary.org/obo/GO_0042632) (cholesterol homeostasis), [GO:0048188](http://purl.obolibrary.org/obo/GO_0048188) (Set1C/COMPASS complex), [GO:0047372](http://purl.obolibrary.org/obo/GO_0047372) (acylglycerol lipase activity), [GO:0005769](http://purl.obolibrary.org/obo/GO_0005769) (early endosome), [GO:0005768](http://purl.obolibrary.org/obo/GO_0005768) (endosome), [GO:0043691](http://purl.obolibrary.org/obo/GO_0043691) (reverse cholesterol transport), [GO:0072562](http://purl.obolibrary.org/obo/GO_0072562) (blood microparticle), [GO:0031410](http://purl.obolibrary.org/obo/GO_0031410) (cytoplasmic vesicle), [GO:0034366](http://purl.obolibrary.org/obo/GO_0034366) (spherical high-density lipoprotein particle), [GO:0031012](http://purl.obolibrary.org/obo/GO_0031012) (extracellular matrix), [GO:0030169](http://purl.obolibrary.org/obo/GO_0030169) (low-density lipoprotein particle binding), [GO:0017127](http://purl.obolibrary.org/obo/GO_0017127) (cholesterol transporter activity), [GO:0034361](http://purl.obolibrary.org/obo/GO_0034361) (very-low-density lipoprotein particle), [GO:0042406](http://purl.obolibrary.org/obo/GO_0042406) (extrinsic component of endoplasmic reticulum membrane), [GO:0042803](http://purl.obolibrary.org/obo/GO_0042803) (protein homodimerization activity), [GO:0034364](http://purl.obolibrary.org/obo/GO_0034364) (high-density lipoprotein particle), [GO:0034363](http://purl.obolibrary.org/obo/GO_0034363) (intermediate-density lipoprotein particle), [GO:0007042](http://purl.obolibrary.org/obo/GO_0007042) (lysosomal lumen acidification), [GO:0034362](http://purl.obolibrary.org/obo/GO_0034362) (low-density lipoprotein particle), [GO:0051082](http://purl.obolibrary.org/obo/GO_0051082) (unfolded protein binding), [GO:0005783](http://purl.obolibrary.org/obo/GO_0005783) (endoplasmic reticulum), [GO:0005543](http://purl.obolibrary.org/obo/GO_0005543) (phospholipid binding), [GO:0006633](http://purl.obolibrary.org/obo/GO_0006633) (fatty acid biosynthetic process), [GO:0060697](http://purl.obolibrary.org/obo/GO_0060697) (positive regulation of phospholipid catabolic process), [GO:0006631](http://purl.obolibrary.org/obo/GO_0006631) (fatty acid metabolic process), [GO:0009986](http://purl.obolibrary.org/obo/GO_0009986) (cell surface), [GO:0006869](http://purl.obolibrary.org/obo/GO_0006869) (lipid transport), [GO:1990871](http://purl.obolibrary.org/obo/GO_1990871) (Vma12-Vma22 assembly complex), [GO:0006629](http://purl.obolibrary.org/obo/GO_0006629) (lipid metabolic process), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0070653](http://purl.obolibrary.org/obo/GO_0070653) (high-density lipoprotein particle receptor binding), [GO:0050821](http://purl.obolibrary.org/obo/GO_0050821) (protein stabilization), [GO:0033700](http://purl.obolibrary.org/obo/GO_0033700) (phospholipid efflux), [GO:0052689](http://purl.obolibrary.org/obo/GO_0052689) (carboxylic ester hydrolase activity), [GO:0016787](http://purl.obolibrary.org/obo/GO_0016787) (hydrolase activity), [GO:0019899](http://purl.obolibrary.org/obo/GO_0019899) (enzyme binding), 

**Class expressions from DL-Learner:**

- Thing 55.61%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) 51.30%
- [GO:0070062](http://purl.obolibrary.org/obo/GO_0070062) (extracellular exosome) 50.65%
- [GO:0034366](http://purl.obolibrary.org/obo/GO_0034366) (spherical high-density lipoprotein particle) 50.65%
- [GO:0034364](http://purl.obolibrary.org/obo/GO_0034364) (high-density lipoprotein particle) 50.65%
- [GO:0034363](http://purl.obolibrary.org/obo/GO_0034363) (intermediate-density lipoprotein particle) 50.65%
- [GO:0034362](http://purl.obolibrary.org/obo/GO_0034362) (low-density lipoprotein particle) 50.65%
- [GO:0034361](http://purl.obolibrary.org/obo/GO_0034361) (very-low-density lipoprotein particle) 50.65%
- [GO:0005615](http://purl.obolibrary.org/obo/GO_0005615) (extracellular space) 50.65%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) 47.32%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:2001221](http://purl.obolibrary.org/obo/GO_2001221) (obsolete positive regulation of G2 phase of mitotic cell cycle)) 47.32%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:2001220](http://purl.obolibrary.org/obo/GO_2001220) (obsolete negative regulation of G2 phase of mitotic cell cycle)) 47.32%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:2001219](http://purl.obolibrary.org/obo/GO_2001219) (obsolete positive regulation of S/G2 transition of mitotic cell cycle)) 47.32%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:2001218](http://purl.obolibrary.org/obo/GO_2001218) (obsolete negative regulation of S/G2 transition of mitotic cell cycle)) 47.32%
- [GO:0034358](http://purl.obolibrary.org/obo/GO_0034358) (plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:2001217](http://purl.obolibrary.org/obo/GO_2001217) (obsolete regulation of S/G2 transition of mitotic cell cycle)) 47.32%


